BS_3F5PR9GS
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 109.68
- os_event
- false
- age_years
- 1.655
- sex
- M
- race
- White
- new_clusters
- S2
- umap1_2d
- -0.269714355
- umap2_2d
- -7.998356147
- umap1_3d
- -3.4857291
- umap2_3d
- -2.52424884
- umap3_3d
- 6.116406551
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.390
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V2+0.290
- E2F_TARGETS+0.270
- MITOTIC_SPINDLE+0.270
- UV_RESPONSE_DN+0.150
- ANDROGEN_RESPONSE+0.080
- MTORC1_SIGNALING+0.060
- HEDGEHOG_SIGNALING+0.040
- APICAL_SURFACE+0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.350
- TGF_BETA_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.300
- XENOBIOTIC_METABOLISM-0.280
- MYOGENESIS-0.270
- APOPTOSIS-0.260
- COMPLEMENT-0.260
- COAGULATION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195671 | — | — | 0.866 |
| 2 | MDT-AP-0138 | Med | Medulloblastoma | 0.866 |
| 3 | BS_3F5PR9GS | medulloblastoma | — | 0.861 |
| 4 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.859 |
| 5 | SRR5088819 | — | — | 0.854 |
| 6 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.851 |
| 7 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.850 |
| 8 | MDT-AP-0184 | Med | Medulloblastoma | 0.849 |
| 9 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.846 |
| 10 | BS_7XQRH69M | medulloblastoma | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |